Publication date: September 2014
Source:Leukemia Research, Volume 38, Issue 9
Author(s): Kami Maddocks , Amy S. Ruppert , Rebekah Browning , Jeffrey Jones , Joseph Flynn , Cheryl Kefauver , Yue Gao , Yao Jiang , Darlene M. Rozewski , Ming Poi , Mitch A. Phelps , Erica Harper , Amy J. Johnson , John C. Byrd , Leslie A. Andritsos
Adequate dosing of lenalidomide in Chronic Lymphocytic Leukemia (CLL) remains unclear. This study determined maximum tolerated dose (MTD) in relapsed CLL patients (Cohort A) and patients achieving a partial response (PR) or better to recent therapy (Cohort B). Thirty-seven patients were enrolled. MTD was 2.5mg followed by 5.0mg continuous. In Cohort A, tumor flare grade 1–2 occurred in 15 patients (50%) and grade 3 in 1 patient (3%). Cohort A had 19 of 23 evaluable (83%) patients, 4 PR (17%) and 15 (65%) stable disease (SD), Cohort B had 6 of 7 patients (86%) with SD. Despite overall response rate not being high, many patients remained on therapy several months with SD.
via ScienceDirect Publication: Leukemia Research